Incyte's Opzelura vitiligo data published in NEJM

20 October 2022

Data on Incyte’s (Nasdaq: INCY) Opzelura (ruxolitinib) cream from the pivotal Phase III TRuE-V clinical trial program have been published in The New England Journal of Medicine (NEJM).

Following an earlier approval in atopic dermatitis, the novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib was approved in July this year by the US Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older.

"These data reinforce the potential that this new medical treatment can have for people who are interested in repigmentation"The data - which showed that the application of the cream resulted in significant facial and total body repigmentation versus vehicle-control at week 24 and a higher proportion of patients responding at week 52 - served as basis for the FDA approval.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK